{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43"}]}],"title":"AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or was a medically important event.","groups":[{"description":"Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15; lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity (up to 20 cycles)","id":"OG000","title":"Ixazomib+Lenalidomide+Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Safety population was defined as all participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","type":"PRIMARY","unitOfMeasure":"participants"}